| [1] |
La Selva D, Kozarek R A, Dorer R K, et al. Primary and metastatic melanoma of the GI tract: clinical presentation, endoscopic findings, and patient outcomes[J]. Surg Endosc, 2020, 34(10): 4456-4462.
|
| [2] |
Marak J R, Kumar T, Dwivedi S, et al. Primary malignant melanoma of the small bowel: a case report[J]. Radiol Case Rep, 2024, 19(3): 1215-1221.
|
| [3] |
Kohoutova D, Worku D, Aziz H, et al. Malignant melanoma of the gastrointestinal tract: symptoms, diagnosis, and current treatment options[J]. Cells, 2021, 10(2): 327.
|
| [4] |
Kaya E, Aksoy T, Güner A L, et al. Colonic malignant melanoma: 18F-FDG PET/CT findings[J]. Mol Imaging Radionucl Ther, 2018, 27(3): 144-145.
|
| [5] |
Tirumani H, Rosenthal M H, Tirumani S H, et al. Imaging of uncommon esophageal malignancies[J]. Dis Esophagus, 2015, 28(6): 552-559.
|
| [6] |
谷俊杰, 李彩莉, 代杰, 等. 79例食管恶性黑色素瘤的免疫治疗疗效及预后影响因素[J]. 中国肿瘤生物治疗杂志, 2023, 30(7): 612-615.
|
|
Gu J J, Li C L, Dai J, et al. Immunotherapy efficacy in 79 patients with malignant esophageal melanoma and the prognostic factors[J]. Chinese Journal of Cancer Biotherapy, 2023, 30(7): 612-615.
|
| [7] |
Cazzato G, Cascardi E, Colagrande A, et al. The thousand faces of malignant melanoma: a systematic review of the primary malignant melanoma of the esophagus[J]. Cancers, 2022, 14(15): 3725.
|
| [8] |
Cheng L, Guo Z Y, Lei L, et al. Treatment and prognosis of primary malignant melanoma of the esophagus[J]. Transl Cancer Res, 2020, 9(7): 4141-4147.
|
| [9] |
Iwanuma Y, Tomita N, Amano T, et al. Current status of primary malignant melanoma of the esophagus: clinical features, pathology, management and prognosis[J]. J Gastroenterol, 2012, 47(1): 21-28.
|
| [10] |
De Nardi P, Guida S, Damiano G, et al. Primary melanoma of the gastrointestinal tract[J]. World J Gastroenterol, 2026, 32(8): 114571.
|
| [11] |
Deng L, Wang H Y, Hu C F, et al. Comprehensive molecular findings in primary malignant melanoma of the esophagus: a multicenter study[J]. Pigment Cell Melanoma Res, 2024, 37(3): 363-371.
|
| [12] |
Ito S, Tachimori Y, Terado Y, et al. Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report[J]. J Med Case Rep, 2021, 15(1): 237.
|
| [13] |
Ye W J, Leng C S, Chen J Y, et al. Characteristics analyses and tumor staging proposal for primary malignant melanoma of the esophagus: a retrospective study[J]. Dis Esophagus, 2025, 38(1): doaf009.
|
| [14] |
Iwasaki K, Ota Y, Yamada E, et al. Primary malignant melanoma of the esophagus with multiple lymph node metastases: a case report and literature review[J]. Medicine, 2020, 99(22): e18573.
|
| [15] |
Yoshinami Y, Nishimura E, Hosokai T, et al. Rare malignant neoplasm of the esophagus: current status and future perspectives[J]. Jpn J Clin Oncol, 2024, 54(2): 111-120.
|
| [16] |
Hashimoto T, Makino T, Yamasaki M, et al. Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus[J]. Oncol Lett, 2019, 18(2): 1872-1880.
|
| [17] |
Allen A C, Spitz S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis[J]. Cancer, 1953, 6(1): 1-45.
|
| [18] |
Keeley J L, Rooney J A, Guzauskas A C, et al. Primary malignant melanoma of the esophagus[J]. Surgery, 1957, 42(3): 607-614.
|
| [19] |
Ferro F E, Miller E W, Morningstar W A, et al. Primary melanoma of the esophagus[J]. AMA Arch Surg, 1958, 76(4): 492-495.
|
| [20] |
刘肖琼, 马钊, 陈传贵, 等. 原发性食管恶性黑色素瘤的临床及预后分析[J]. 中华胃肠外科杂志, 2016, 19(1): 86-87.
|
|
Liu X Q, Ma Z, Chen C G, et al. Clinical and prognostic analysis of primary malignant melanoma of esophagus[J]. Chinese Journal of Gastrointestinal Surgery, 2016, 19(1): 86-87.
|
| [21] |
魏雪静, 张彦宁, 柳玮华, 等. 食管原发性恶性黑色素瘤[J]. 中华病理学杂志, 2018, 47(7): 548-550.
|
|
Wei X J, Zhang Y N, Liu W H, et al. Primary malignant melanoma of esophagus[J]. Chinese Journal of Pathology, 2018, 47(7): 548-550.
|
| [22] |
魏雪静, 张彦宁, 徐瑞, 等. 原发性消化道黑色素瘤14例临床病理分析[J]. 临床与实验病理学杂志, 2021, 37(6): 655-659.
|
|
Wei X J, Zhang Y N, Xu R, et al. Clinical pathologic analysis of the primary gastrointestinal melanoma[J]. Chinese Journal of Clinical and Experimental Pathology, 2021, 37(6): 655-659.
|
| [23] |
Dai L, Wang Z M, Xue Z Q, et al. Results of surgical treatment for primary malignant melanoma of the esophagus: a multicenter retrospective study[J]. J Thorac Cardiovasc Surg, 2021, 161(1): 294-302.
|
| [24] |
Haugh A, Daud A I. Therapeutic strategies in BRAF V600 wild-type cutaneous melanoma[J]. Am J Clin Dermatol, 2024, 25(3): 407-419.
|
| [25] |
DuBose E, Bevill S M, Mitchell D K, et al. Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition[J]. Front Oncol, 2024, 14: 1191217.
|
| [26] |
Liu Y, Xia H, Wang Y M, et al. Prognosis and immunotherapy in melanoma based on selenoprotein k-related signature[J]. Int Immunopharmacol, 2024, 137: 112436.
|
| [27] |
He Z S, Lyu J, Lyu L C, et al. Identification of a metabolism-linked genomic signature for prognosis and immunotherapeutic efficiency in metastatic skin cutaneous melanoma[J]. Medicine, 2024, 103(23): e38347.
|
| [28] |
Sussman T A, Severgnini M, Giobbie-Hurder A, et al. Phase Ⅱ trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stageⅢ and IV melanoma[J]. Front Oncol, 2024, 14: 1395978.
|
| [29] |
Mørk S K, Skadborg S K, Albieri B, et al. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma[J]. J Immunother Cancer, 2024, 12(5): e008817.
|